title: One acute promyelocytic leukemia patient underwent complete molecular remission with consistent presence of t (2; 3) (p25; q21) karyotype.
abstract: OBJECTIVE
  This study aimed to explore why one acute promyelocytic leukemia (APL) patient underwent complete molecular remission in the persistent presence of the t (2; 3) (p25; q21) karotype.
  
  
  METHODS
  One APL patient overexpressed PML/RARα (bcr1) and WT1 genes in the presence of the Fms-like tyrosine kinase-internal tandem duplication mutation, while cytogenetics showed t (2; 3) (p25; q21) and t (15; 17) (q22; q21). Cytogenetics and molecular biology were monitored throughout the treatment.
  
  
  RESULTS
  After 5 weeks of induction chemotherapy, this case gained complete molecular biology remission with the presence of t (2; 3) (p25; q21). This status was still present during the follow-up consolidate and maintenance therapy.
  
  
  CONCLUSIONS
  For this patient, t (2; 3) (p25; q21) may be one kind of balanced translocation that leads to miscarriages or causes abnormalities in children, unrelated to leukemia or other malignancies.
authors.affiliation: Huazhong University of Science & Technology, Union Hospital, Institute of Hematology, Tongji Medical College , Jiefang Road 1277#, Jianghan District, Wuhan, Hubei Province 430022 , China +86 27 85726387 ; +86 27 85726387 ; zhangmin35@aliyun.com.
authors.forename: Yong
authors.initials: Y
authors.lastname: You
authors.forename: Yanli
authors.initials: Y
authors.lastname: He
authors.forename: Jing
authors.initials: J
authors.lastname: Zou
authors.forename: Jine
authors.initials: J
authors.lastname: Zheng
authors.forename: Lei
authors.initials: L
authors.lastname: Chen
authors.forename: Xiaoqing
authors.initials: X
authors.lastname: Li
authors.forename: Ping
authors.initials: P
authors.lastname: Zou
authors.forename: Min
authors.initials: M
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics*; D002893:Chromosomes, Human, Pair 3 / Q000235:genetics*; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D016162:Genes, Wilms Tumor; D006801:Humans; D060828:Induction Chemotherapy; D059785:Karyotype; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics*; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D012074:Remission Induction; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage; D055815:Young Adult; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D015514:Oncogene Proteins, Fusion; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D003630:Daunorubicin